Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract-Case Study: Tenapanor
A physiologically based biopharmaceutics model (PBBM) was developed to predict stool and urine sodium content in response to tenapanor administration in healthy subjects. Tenapanor is a minimally absorbed small molecule that inhibits the sodium/hydrogen isoform 3 exchanger (NHE3). It is used to trea...
Saved in:
Main Authors: | Konstantinos Stamatopoulos (Author), Nena Mistry (Author), Nikoletta Fotaki (Author), David B. Turner (Author), Brandon Swift (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
by: Konstantinos Stamatopoulos, et al.
Published: (2023) -
Use of In Vitro Dynamic Colon Model (DCM) to Inform a Physiologically Based Biopharmaceutic Model (PBBM) to Predict the In Vivo Performance of a Modified-Release Formulation of Theophylline
by: Konstantinos Stamatopoulos, et al.
Published: (2023) -
A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP
by: Marival Bermejo, et al.
Published: (2020) -
Non-Absorbable Oral Gentamicin Sulphate: Biopharmaceutical and Dosage Form Evaluation
by: Nwakile Dozie C., et al.
Published: (2021) -
Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease
by: Tiffany Lin, et al.
Published: (2022)